Tysabri and PML: Understanding the Statute of Limitations for Claims in New Jersey

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Literacy to Specific Occupational Risk

The legacy of general health and science information has long emphasized the importance of informed decision-making in medical treatments. Within this broad context, the monitoring of therapeutic interventions has evolved to include not only efficacy but also long-term safety profiles. One area of particular focus has been the relationship between biologic therapies and adverse outcomes, where patient education and risk communication are paramount. This foundational understanding of health information dissemination provides a necessary backdrop for examining specific cases where treatment risks intersect with legal and occupational considerations. Transitioning from this general framework, attention now turns to the occupational exposure concern associated with Tysabri, a medication used in certain chronic conditions. The focus narrows to the risk of Progressive Multifocal Leukoencephalopathy, a serious condition that has prompted legal scrutiny, particularly regarding settlements in New Jersey. The statute of limitations for such claims becomes a critical factor for individuals who may have been exposed to the drug in a professional capacity, such as healthcare workers or pharmaceutical handlers. This pivot from broad health literacy to a targeted occupational risk underscores the need for clear timelines and legal awareness in managing exposure-related liabilities. The shift highlights how general health principles must adapt to specific, real-world scenarios where professional environments introduce unique vulnerabilities.

Tysabri and PML: Medical Evidence and Risk Factors

Tysabri (natalizumab) is a monoclonal antibody approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical evidence and postmarketing surveillance. Three primary risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label instructs healthcare professionals to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patient enrollment and education about PML risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte adhesion and migration across the blood-brain barrier, Tysabri reduces immune surveillance in the central nervous system. This immunosuppressive effect can allow latent JC virus, which is present in many individuals, to reactivate and cause PML. The label notes that PML "typically only occurs in patients who are immunocompromised" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation of PML includes progressive neurological deficits such as weakness, cognitive changes, visual disturbances, and ataxia. Diagnosis is confirmed by MRI findings and detection of JC virus DNA in cerebrospinal fluid via PCR.

Legal Implications: Statute of Limitations in New Jersey

For patients who develop PML after Tysabri exposure, the timeline between drug initiation and symptom onset can vary. The label reports that herpes infections have occurred "a few months to several years" after starting Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), and PML risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency period is critical for legal considerations, as the statute of limitations for filing a claim in New Jersey typically begins when the injury is discovered or reasonably should have been discovered. For PML, this discovery date may be when symptoms first appear or when a diagnosis is confirmed. The adequacy of warnings regarding Tysabri and PML is a central issue in settlement considerations. The boxed warning clearly states the risk and identifies specific risk factors. However, affected patients may argue that the warnings were insufficient or that healthcare providers did not adequately communicate the risk. The TOUCH Prescribing Program is designed to ensure patients are informed, but program compliance and documentation may vary. Settlement-related considerations for affected patients include the severity of PML outcomes—"usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962)—and the need for ongoing medical care. Patients may seek compensation for medical expenses, lost income, and pain and suffering. In New Jersey, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered. For PML, this means patients must file a claim within two years of receiving a diagnosis or recognizing that their symptoms are linked to Tysabri. Given the latency period, patients may need to act promptly once PML is confirmed. Legal counsel should review the specific timeline of Tysabri exposure, symptom onset, and diagnosis to determine if the claim is timely.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in New Jersey?

In New Jersey, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, this means patients must file a claim within two years of receiving a diagnosis or recognizing that their symptoms are linked to Tysabri. Given the latency period, patients may need to act promptly once PML is confirmed. Legal counsel should review the specific timeline of Tysabri exposure, symptom onset, and diagnosis to determine if the claim is timely.

What are the primary risk factors for PML in Tysabri patients?

Three primary risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The FDA boxed warning states that Tysabri increases the risk of PML, an opportunistic viral infection that usually leads to death or severe disability.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA Boxed Warning for Tysabri (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.